College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, China.
Centre of Biomedical Research & Development, Fujian University of Traditional Chinese Medicine, Fuzhou, China.
Front Cell Infect Microbiol. 2021 Aug 19;11:634780. doi: 10.3389/fcimb.2021.634780. eCollection 2021.
Hyperlipidemia, defined as the presence of excess fat or lipids in the blood, has been considered as a high-risk factor and key indicator of many metabolic diseases. The gut microbiota has been reported playing a vital role in regulating host lipid metabolism. The pathogenic role of gut microbiota in the development of hyperlipidemia has been revealed through fecal microbiota transplantation experiment to germ-free mice. The effector mechanism of microbiota-related metabolites such as bile acids, lipopolysaccharide, and short-chain fatty acids in the regulation of hyperlipidemia has been partially unveiled. Moreover, studies on gut-microbiota-targeted hyperlipidemia interventions, including the use of prebiotics, probiotics, fecal microbiota transplantation, and natural herbal medicines, also have shown their efficacy in the treatment of hyperlipidemia. In this review, we summarize the relationship between gut microbiota and hyperlipidemia, the impact of gut microbiota and microbiota-related metabolites on the development and progression of hyperlipidemia, and the potential therapeutic management of hyperlipidemia targeted at gut microbiota.
高脂血症，定义为血液中存在过量的脂肪或脂质，被认为是许多代谢性疾病的高危因素和关键指标。肠道微生物群已被报道在调节宿主脂质代谢方面发挥着重要作用。通过对无菌小鼠进行粪便微生物群移植实验，揭示了肠道微生物群在高脂血症发展中的致病作用。微生物相关代谢物如胆汁酸、脂多糖和短链脂肪酸在调节高脂血症中的作用机制已部分揭示。此外，针对肠道微生物群的高脂血症干预研究，包括使用益生元、益生菌、粪便微生物群移植和天然草药，也已经显示出它们在治疗高脂血症方面的疗效。在这篇综述中，我们总结了肠道微生物群与高脂血症的关系，肠道微生物群及其相关代谢物对高脂血症发生和发展的影响，以及针对肠道微生物群的高脂血症潜在治疗管理。
